SpliSense

Jerusalem, Israel Founded: 2016 • Age: 10 yrs
Limited information available
Request Access

About SpliSense

SpliSense is a company based in Jerusalem (Israel) founded in 2016.. SpliSense has raised $28.5 million across 2 funding rounds from investors including Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund. SpliSense offers products and services including SPL84, SPL5AC, SPL5B, and SPL23. SpliSense operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others.

  • Headquarter Jerusalem, Israel
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $28.5 M (USD)

    in 2 rounds

  • Latest Funding Round
    $28.5 M (USD), Series B

    May 13, 2021

  • Investors
    Orbimed

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SpliSense

SpliSense offers a comprehensive portfolio of products and services, including SPL84, SPL5AC, SPL5B, and SPL23. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets cystic fibrosis using ASOs to modify protein function.

Addresses muco-obstructive diseases through RNA-based interventions.

Focuses on pulmonary conditions via Antisense Oligonucleotides.

Develops treatments for additional pulmonary disease opportunities.

People of SpliSense
Headcount 10-50
Employee Profiles 6
Employee Profiles
People
Asaf Cohen
VP CMC
People
Lital Friedman
VP Clinical And Regulatory Affairs
People
Renana Elgrabli רננה אלגרבלי
Senior Researcher
People
Chava Stampfer
Senior Researcher

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of SpliSense

SpliSense has successfully raised a total of $28.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $28.5 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $28.5M
  • First Round

    (01 Jun 2017)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2021 Amount Series B - SpliSense Valuation Cystic Fibrosis Foundation , Orbimed
Jun, 2017 Amount Grant - SpliSense Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SpliSense

SpliSense has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
-
Founded Year Domain Location
Israeli life science ventures are funded by Integra Holdings.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SpliSense

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SpliSense

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Splisense Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SpliSense

SpliSense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cell and gene therapies for multiple disorders are developed.
domain founded_year HQ Location
Software development services are provided for the biopharma sector.
domain founded_year HQ Location
Services for cell therapy development and manufacturing are provided.
domain founded_year HQ Location
Development and manufacturing services for cell-based therapies are provided.
domain founded_year HQ Location
Cell and gene therapeutic services are provided to biopharmaceutical firms.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about SpliSense

When was SpliSense founded?

SpliSense was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is SpliSense located?

SpliSense is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.

Is SpliSense a funded company?

SpliSense is a funded company, having raised a total of $28.5M across 2 funding rounds to date. The company's 1st funding round was a Grant of $400K, raised on Jun 01, 2017.

What does SpliSense do?

SpliSense was founded in 2016 and is headquartered in Jerusalem, Israel. The companys domain is registered as splisense.com. Limited information is available concerning its industry sector, core operations, or specific services. Details on business activities and geographical scope beyond the founding location are not provided in current records. Further data would be required for a comprehensive overview.

Who are the top competitors of SpliSense?

SpliSense's top competitors include Ori Biotech, MaSTherCell and OBiO Technology.

What products or services does SpliSense offer?

SpliSense offers SPL84, SPL5AC, SPL5B, and SPL23.

Who are SpliSense's investors?

SpliSense has 4 investors. Key investors include Orbimed, Cystic Fibrosis Foundation, Israel Biotech Fund, and Integra Holdings.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available